PharmaBiome AG
Based on our research, we believe that the common denominator underlying each intestinal microbiome is a network of interconnected, interdependent and metabolic functions that are essential for the host and the microbiome. PharmaBiome has developed unique technologies to access the entire range of intestinal bacteria for the design and production of function-based consortia at scale. We are a pre-clinical stage spinoff from the ETH Zurich, combining key expertise in microbiology, biotechnology and the molecular disease mechanisms that involve the microbiome.
Company details
Find locations served, office locations
- Business Type:
- Service provider
- Industry Type:
- Medical Research
- Market Focus:
- Internationally (various countries)
About Us
We unlock the therapeutic potential of the microbiome through our deep understanding of microbial function, host-microbiome interactions and disease-specific dynamics, enabling us to discover and develop therapeutics and bring the hope for cure to patients.
We strive to become the leading global experts in the development of bacterial consortia based on mixed cultures. Our mission is to unlock the therapeutic potential of the microbiome through a deep understanding of its function and the disease-specific dynamics.